Agents and methods for treating myopathies
AssigneesImplicit Bioscience Limited, Belth Israel Deaconess Medical Center. Inc.
InventorsKory Joshua Lavine, Jeffrey E. Saffiz
Life of this patent
Estimating the term…
Abstract
This disclosure relates generally to methods and agents for treating cardiomyopathies. More particularly, the present disclosure relates to the use of CD14 antagonist antigen-binding molecules for treating a cardiomyopathy, including alleviating or inhibiting the development of adverse cardiac remodeling, improving cardiac function including improving ventricular function and atrial function.
Claims20
A method of treating or alleviating at least one symptom of a cardiomyopathy in a subject, the method comprising, consisting or consisting essentially of administering to the subject a CD14 antagonist antigen-binding molecule.
A method of alleviating or inhibiting development of adverse cardiac remodeling in a subject with a cardiomyopathy, the method comprising, consisting or consisting essentially of administering to the subject a CD14 antagonist antigen-binding molecule.
A method of improving cardiac function in a subject with a cardiomyopathy, the method comprising, consisting or consisting essentially of administering to the subject a CD14 antagonist antigen-binding molecule.
A method of improving ventricular function in a subject with a cardiomyopathy, the method comprising, consisting or consisting essentially of administering to the subject a CD14 antagonist antigen-binding molecule.
A method of improving atrial function in a subject with a cardiomyopathy, the method comprising, consisting or consisting essentially of administering to the subject a CD14 antagonist antigen-binding molecule.
A method of treating or alleviating at least one symptom of ACM in a subject, the method comprising, consisting or consisting essentially of administering to the subject a CD14 antagonist antigen-binding molecule.
A method of reducing the number of premature ventricular contractions (PVCs) in a subject, the method comprising, consisting or consisting essentially of administering to the subject a CD14 antagonist antigen-binding molecule.
A method of treating or alleviating a symptom of atrial fibrillation in a subject, the method comprising, consisting or consisting essentially of administering to a subject having or at risk of developing atrial fibrillation a CD14 antagonist antigen-binding molecule.
A method of reducing the number of premature atrial contractions (PACs) in a subject, the method comprising, consisting or consisting essentially of administering to the subject a CD14 antagonist antigen-binding molecule.
Dependencies are inferred from the claim text.